8-K Announcements
6Material company update
Mar 20, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 9, 2026·SEC
Iovance Biotherapeutics, Inc.(IOVA)Earnings, Financials & Key Ratios
IOVA•NASDAQ
$4.09
$1.68B mkt cap·Price updated May 6, 2026
AboutIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Show more
- Revenue$264M+60.6%
- EBITDA-$367M-4.5%
- Net Income-$391M-5.1%
- EPS (Diluted)-1.09+14.8%
- Gross Margin97.23%+298.1%
- EBITDA Margin-139.44%+34.9%
- Operating Margin-153.08%+36.5%
- Net Margin-148.38%+34.6%
- ROE-55.5%+3.4%
- ROIC-48.91%+1.1%
- Debt/Equity0.07-15.4%
IOVA Key Insights
Iovance Biotherapeutics, Inc. (IOVA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 23.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IOVA Price & Volume
Iovance Biotherapeutics, Inc. (IOVA) stock price & volume — 10-year historical chart
Loading chart...
IOVA Growth Metrics
Iovance Biotherapeutics, Inc. (IOVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM60.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.15%
Return on Capital
10 Years-53.81%
5 Years-58.43%
3 Years-59.99%
Last Year-51.62%
IOVA Recent Earnings
Iovance Biotherapeutics, Inc. (IOVA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (27%)
Q1 2026Latest
Feb 24, 2026EPS
$0.18
Est $0.22
+18.2%
Revenue
$87M
Est $81M
+7.4%
Q4 2025
Nov 6, 2025EPS
$0.25
Est $0.29
+13.8%
Revenue
$67M
Est $82M
-17.9%
Q3 2025
Aug 7, 2025EPS
$0.33
Est $0.29
-13.8%
Revenue
$60M
Est $78M
-23.5%
Q2 2025
May 8, 2025EPS
$0.36
Est $0.25
-44.0%
Revenue
$49M
Est $82M
-40.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.18vs $0.22+18.2% | $87Mvs $81M+7.4% |
| Q4 2025 | Nov 6, 2025 | $0.25vs $0.29+13.8% | $67Mvs $82M-17.9% |
| Q3 2025 | Aug 7, 2025 | $0.33vs $0.29-13.8% | $60Mvs $78M-23.5% |
| Q2 2025 | May 8, 2025 | $0.36vs $0.25-44.0% | $49Mvs $82M-40.1% |
Based on last 12 quarters of dataView full earnings history →
IOVA Peer Comparison
Iovance Biotherapeutics, Inc. (IOVA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADCT | 490.96M | 3.86 | -3.45 | 14.85% | -173.02% | |||
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare IOVA vs Peers
Iovance Biotherapeutics, Inc. (IOVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IOVA Income Statement
Iovance Biotherapeutics, Inc. (IOVA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1.19M | 164.07M | 263.5M |
| Revenue Growth % | - | - | - | - | - | - | - | 13698.99% | 60.6% |
| Cost of Goods Sold | 952K | 956K | 8.12M | 0 | 0 | 0 | 10.76M | 124M | 7.29M |
| COGS % of Revenue | - | - | - | - | - | - | 904.54% | 75.57% | 2.77% |
| Gross Profit | -952K▲ 0% | -956K▼ 0.4% | -8.12M▼ 749.7% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -9.57M▲ 0% | 40.08M▲ 518.9% | 256.22M▲ 539.3% |
| Gross Margin % | - | - | - | - | - | - | -804.54% | 24.43% | 97.23% |
| Gross Profit Growth % | 2.66% | -0.42% | -749.69% | 100% | - | - | - | 518.93% | 539.34% |
| Operating Expenses | 92.88M | 128.26M | 206.87M | 261.94M | 342.7M | 398.88M | 450.99M | 435.35M | 659.57M |
| OpEx % of Revenue | - | - | - | - | - | - | 37930.45% | 265.35% | 250.31% |
| Selling, General & Admin | 21.26M | 28.43M | 40.85M | 60.21M | 83.66M | 104.1M | 106.92M | 153.02M | 152.32M |
| SG&A % of Revenue | - | - | - | - | - | - | 8992.09% | 93.26% | 57.81% |
| Research & Development | 71.61M | 99.83M | 166.02M | 201.73M | 259.04M | 294.78M | 344.08M | 282.34M | 300.27M |
| R&D % of Revenue | - | - | - | - | - | - | 28938.35% | 172.08% | 113.95% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 206.98M |
| Operating Income | -92.88M▲ 0% | -128.26M▼ 38.1% | -206.87M▼ 61.3% | -261.94M▼ 26.6% | -342.7M▼ 30.8% | -398.88M▼ 16.4% | -460.56M▼ 15.5% | -395.28M▲ 14.2% | -403.36M▼ 2.0% |
| Operating Margin % | - | - | - | - | - | - | -38734.99% | -240.92% | -153.08% |
| Operating Income Growth % | -73.15% | -38.09% | -61.29% | -26.62% | -30.83% | -16.39% | -15.46% | 14.17% | -2.04% |
| EBITDA | -91.92M | -127.3M | -198.75M | -260.8M | -328.72M | -377.74M | -427.43M | -351.67M | -367.42M |
| EBITDA Margin % | - | - | - | - | - | - | -35948.86% | -214.34% | -139.44% |
| EBITDA Growth % | -74.56% | -38.48% | -56.12% | -31.22% | -26.05% | -14.91% | -13.15% | 17.72% | -4.48% |
| D&A (Non-Cash Add-back) | 952K | 956K | 8.12M | 1.14M | 13.98M | 21.14M | 33.13M | 43.61M | 35.94M |
| EBIT | -92.06M | -123.58M | -197.56M | -261.94M | -342.7M | -398.88M | -460.56M | -395.28M | -393.05M |
| Net Interest Income | 0 | 0 | 9.32M | 2.36M | 451K | 0 | 13.04M | 20.27M | 0 |
| Interest Income | 813K | 0 | 9.32M | 2.36M | 451K | 2.98M | 13.04M | 20.27M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 2.98M | 0 | 0 | 0 |
| Other Income/Expense | 813K | 4.68M | 9.32M | 2.36M | 451K | 2.98M | 13.04M | 20.27M | 10.31M |
| Pretax Income | -92.06M▲ 0% | -123.58M▼ 34.2% | -197.56M▼ 59.9% | -259.58M▼ 31.4% | -342.25M▼ 31.8% | -395.89M▼ 15.7% | -447.52M▼ 13.0% | -375M▲ 16.2% | -393.05M▼ 4.8% |
| Pretax Margin % | - | - | - | - | - | - | -37638.02% | -228.56% | -149.16% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -3.48M | -2.83M | -2.07M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0.78% | 0.75% | 0.53% |
| Net Income | -92.06M▲ 0% | -123.58M▼ 34.2% | -197.56M▼ 59.9% | -259.58M▼ 31.4% | -342.25M▼ 31.8% | -395.89M▼ 15.7% | -444.04M▼ 12.2% | -372.18M▲ 16.2% | -390.98M▼ 5.1% |
| Net Margin % | - | - | - | - | - | - | -37345.42% | -226.84% | -148.38% |
| Net Income Growth % | -74.05% | -34.23% | -59.86% | -31.4% | -31.85% | -15.67% | -12.16% | 16.18% | -5.05% |
| Net Income (Continuing) | -92.06M | -123.58M | -197.56M | -259.58M | -342.25M | -395.89M | -444.04M | -372.18M | -390.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.41▲ 0% | -1.27▲ 9.9% | -1.50▼ 18.1% | -1.88▼ 25.3% | -2.23▼ 18.6% | -2.49▼ 11.7% | -1.89▲ 24.1% | -1.28▲ 32.3% | -1.09▲ 14.8% |
| EPS Growth % | -46.88% | 9.93% | -18.11% | -25.33% | -18.62% | -11.66% | 24.1% | 32.28% | 14.84% |
| EPS (Basic) | -1.41 | -1.27 | -1.50 | -1.88 | -2.23 | -2.49 | -1.89 | -1.28 | -1.09 |
| Diluted Shares Outstanding | 65.24M | 97.28M | 124.34M | 138.3M | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
| Basic Shares Outstanding | 65.24M | 97.28M | 124.34M | 138.3M | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IOVA Balance Sheet
Iovance Biotherapeutics, Inc. (IOVA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 149.29M | 475.37M | 316.49M | 636.1M | 507.96M | 479.12M | 307.85M | 457.02M | 442.69M |
| Cash & Short-Term Investments | 145.37M | 468.52M | 307.08M | 629.44M | 504.41M | 471.85M | 279.87M | 323.78M | 296.98M |
| Cash Only | 145.37M | 82.15M | 13.97M | 67.33M | 78.23M | 231.73M | 114.89M | 115.69M | 163.08M |
| Short-Term Investments | 0 | 386.37M | 293.11M | 562.11M | 426.18M | 240.11M | 164.98M | 208.09M | 133.9M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 151K | 69.34M | 82.45M |
| Days Sales Outstanding | - | - | - | - | - | - | 46.35 | 154.26 | 114.21 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 10.37M | 51.52M | 51.68M |
| Days Inventory Outstanding | - | - | - | - | - | - | 352 | 151.66 | 2.59K |
| Other Current Assets | 3.92M | 6.85M | 0 | 0 | 0 | 7.27M | 17.46M | 12.38M | 11.58M |
| Total Non-Current Assets | 6.08M | 5.45M | 28.16M | 132.36M | 269.38M | 184.87M | 472.5M | 453.41M | 470.48M |
| Property, Plant & Equipment | 2.45M | 2.68M | 19.23M | 113.92M | 169.92M | 178.25M | 176.54M | 164.28M | 177.01M |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.01x | 1.00x | 1.49x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 229.26M | 282.4M | 279.32M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 91.59M | 0 | 66.43M | 0 | 0 |
| Other Non-Current Assets | 3.63M | 2.76M | 8.93M | 18.44M | 7.87M | 6.62M | 270K | 6.73M | 14.15M |
| Total Assets | 155.37M▲ 0% | 480.82M▲ 209.5% | 344.65M▼ 28.3% | 768.46M▲ 123.0% | 777.33M▲ 1.2% | 663.98M▼ 14.6% | 780.35M▲ 17.5% | 910.43M▲ 16.7% | 913.17M▲ 0.3% |
| Asset Turnover | - | - | - | - | - | - | 0.00x | 0.18x | 0.29x |
| Asset Growth % | -9.61% | 209.46% | -28.32% | 122.96% | 1.15% | -14.58% | 17.53% | 16.67% | 0.3% |
| Total Current Liabilities | 9.89M | 14.4M | 39.08M | 54.87M | 89.2M | 91.48M | 110.31M | 122.34M | 138.36M |
| Accounts Payable | 1.23M | 2.74M | 15.57M | 13.51M | 27.38M | 26.6M | 33.12M | 27.51M | 22.16M |
| Days Payables Outstanding | 472.35 | 1.05K | 699.49 | - | - | - | 1.12K | 80.98 | 1.11K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.04M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.75M | 7.55M | 0 | 0 | 0 | 0 | 34.59M | 50.03M | 112.16M |
| Current Ratio | 15.09x | 33.02x | 8.10x | 11.59x | 5.69x | 5.24x | 2.79x | 3.74x | 3.20x |
| Quick Ratio | 15.09x | 33.02x | 8.10x | 11.59x | 5.69x | 5.24x | 2.70x | 3.31x | 2.83x |
| Cash Conversion Cycle | - | - | - | - | - | - | -725.76 | 224.94 | 1.59K |
| Total Non-Current Liabilities | 297K | 230K | 6.6M | 57.09M | 66.47M | 72.86M | 85.43M | 77.68M | 76.23M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 1M | 1M | 1M | 1M | 44.4M |
| Capital Lease Obligations | 0 | 0 | 4.25M | 45.38M | 65.47M | 71.86M | 67.08M | 44.37M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 17.35M | 32.31M | 31.83M |
| Other Non-Current Liabilities | 297K | 230K | 2.35M | 11.71M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 9.89M | 14.63M | 45.68M | 111.96M | 155.67M | 164.34M | 195.74M | 200.02M | 214.59M |
| Total Debt | 0 | 0 | 11.5M | 51.66M | 71.53M | 85.45M | 75.86M | 58.26M | 48.44M |
| Net Debt | -145.37M | -82.15M | -2.47M | -15.67M | -6.7M | -146.28M | -39.03M | -57.43M | -114.63M |
| Debt / Equity | - | - | 0.04x | 0.08x | 0.12x | 0.17x | 0.13x | 0.08x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | -133.63x | - | - | - |
| Total Equity | 145.48M▲ 0% | 466.19M▲ 220.4% | 298.97M▼ 35.9% | 656.5M▲ 119.6% | 621.66M▼ 5.3% | 499.64M▼ 19.6% | 584.61M▲ 17.0% | 710.4M▲ 21.5% | 698.58M▼ 1.7% |
| Equity Growth % | -12.84% | 220.45% | -35.87% | 119.59% | -5.31% | -19.63% | 17.01% | 21.52% | -1.66% |
| Book Value per Share | 2.23 | 4.79 | 2.40 | 4.75 | 4.05 | 3.14 | 2.49 | 2.45 | 1.95 |
| Total Shareholders' Equity | 145.48M | 466.19M | 298.97M | 656.5M | 621.66M | 499.64M | 584.61M | 710.4M | 698.58M |
| Common Stock | 3K | 5K | 5K | 6K | 7K | 8K | 11K | 13K | 17K |
| Retained Earnings | -249.18M | -372.76M | -570.61M | -830.19M | -1.17B | -1.57B | -2.01B | -2.38B | -2.78B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -42K | 220K | 19K | -601K | -902K | 2.53M | -1.05M | 16.44M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IOVA Cash Flow Statement
Iovance Biotherapeutics, Inc. (IOVA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -78.71M | -101.25M | -158.89M | -205.13M | -227.94M | -292.76M | -361.82M | -352.98M | -302.41M |
| Operating CF Margin % | - | - | - | - | - | - | -30430.61% | -215.14% | -114.77% |
| Operating CF Growth % | -140.94% | -28.64% | -56.93% | -29.11% | -11.12% | -28.44% | -23.59% | 2.44% | 14.33% |
| Net Income | -92.06M | -123.58M | -197.56M | -259.58M | -342.25M | -395.89M | -444.04M | -372.18M | -390.98M |
| Depreciation & Amortization | 952K | 956K | 8.12M | 1.14M | 13.98M | 21.14M | 33.13M | 43.61M | 34.46M |
| Stock-Based Compensation | 11.97M | 20.03M | 24.28M | 40.89M | 69.77M | 84.02M | 62.63M | 109.63M | 61.58M |
| Deferred Taxes | 0 | 0 | 0 | 1.86M | 0 | 0 | -3.48M | -2.83M | -2.07M |
| Other Non-Cash Items | 19K | -1.32M | 8.97M | 7.57M | 6.01M | 871K | -3.54M | -8.65M | 18.87M |
| Working Capital Changes | 416K | 2.67M | -2.7M | 2.98M | 24.55M | -2.89M | -6.52M | -122.56M | -24.27M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -149K | -69.19M | -13.11M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -10.12M | -39.92M | -14.21M |
| Change in Payables | 369K | 1.51M | 0 | -2.96M | 6.98M | 5.88M | 4.83M | -7.84M | -6.66M |
| Cash from Investing | 58.68M | -386.28M | 90.03M | -317.85M | 132K | 256.45M | -155.24M | -96.41M | 47.5M |
| Capital Expenditures | -1.03M | -1.2M | -6.92M | -46.79M | -37.57M | -20.43M | -22.29M | -11.07M | -33.84M |
| CapEx % of Revenue | - | - | - | - | - | - | 1874.68% | 6.75% | 12.84% |
| Acquisitions | 0 | 0 | 0 | 271.06M | -37.71M | -276.88M | -212.63M | -52.57M | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 59.7M | -385.08M | 96.94M | -271.06M | 37.71M | 276.88M | 0 | 0 | 0 |
| Cash from Financing | 58.69M | 424.31M | 6.13M | 576.42M | 239.27M | 190.15M | 462.96M | 390.66M | 300.77M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 1M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | -312K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.25M | 0 | -312K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 5.03M | -373.33M | 6.44M | 9.38M | 35.11M | 648K | -322K | -6.64M | -7.06M |
| Net Change in Cash | 38.66M▲ 0% | -63.22M▼ 263.5% | -62.73M▲ 0.8% | 53.44M▲ 185.2% | 11.46M▼ 78.6% | 153.85M▲ 1242.6% | -56.84M▼ 136.9% | -59.27M▼ 4.3% | 47.38M▲ 180.0% |
| Free Cash Flow | -79.74M▲ 0% | -102.45M▼ 28.5% | -165.81M▼ 61.8% | -251.93M▼ 51.9% | -265.51M▼ 5.4% | -313.18M▼ 18.0% | -384.11M▼ 22.6% | -364.05M▲ 5.2% | -336.24M▲ 7.6% |
| FCF Margin % | - | - | - | - | - | - | -32305.3% | -221.88% | -127.61% |
| FCF Growth % | -133.22% | -28.48% | -61.85% | -51.94% | -5.39% | -17.95% | -22.65% | 5.22% | 7.64% |
| FCF per Share | -1.22 | -1.05 | -1.33 | -1.82 | -1.73 | -1.97 | -1.63 | -1.26 | -0.94 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.82x | 0.80x | 0.79x | 0.67x | 0.74x | 0.81x | 0.95x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IOVA Key Ratios
Iovance Biotherapeutics, Inc. (IOVA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.04% | -58.94% | -40.41% | -51.64% | -54.34% | -53.55% | -70.61% | -81.91% | -57.48% | -55.5% |
| Return on Invested Capital (ROIC) | -10435.6% | -25056.74% | -50.08% | -45.6% | -41.92% | -40.93% | -61.79% | -76.85% | -49.47% | -48.91% |
| Gross Margin | - | - | - | - | - | - | - | -804.54% | 24.43% | 97.23% |
| Net Margin | - | - | - | - | - | - | - | -37345.42% | -226.84% | -148.38% |
| Debt / Equity | - | - | - | 0.04x | 0.08x | 0.12x | 0.17x | 0.13x | 0.08x | 0.07x |
| Interest Coverage | - | - | - | - | - | - | -133.63x | - | - | - |
| FCF Conversion | 0.62x | 0.85x | 0.82x | 0.80x | 0.79x | 0.67x | 0.74x | 0.81x | 0.95x | 0.77x |
| Revenue Growth | - | - | - | - | - | - | - | - | 13698.99% | 60.6% |
IOVA SEC Filings & Documents
Iovance Biotherapeutics, Inc. (IOVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
IOVA Frequently Asked Questions
Iovance Biotherapeutics, Inc. (IOVA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Iovance Biotherapeutics, Inc. (IOVA) reported $263.5M in revenue for fiscal year 2025.
Iovance Biotherapeutics, Inc. (IOVA) grew revenue by 60.6% over the past year. This is strong growth.
Iovance Biotherapeutics, Inc. (IOVA) reported a net loss of $391.0M for fiscal year 2025.
Dividend & Returns
Iovance Biotherapeutics, Inc. (IOVA) has a return on equity (ROE) of -55.5%. Negative ROE indicates the company is unprofitable.
Iovance Biotherapeutics, Inc. (IOVA) had negative free cash flow of $336.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More IOVA
Iovance Biotherapeutics, Inc. (IOVA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates